NeuroBo Pharmaceuticals Inc. [NASDAQ: NRBO] price surged by 7.18 percent to reach at $0.05. The company report on January 18, 2023 that NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Experienced Executive Brings Approximately 40 Years of Pharmaceutical, Clinical Development and Operational Experience.
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced that it has appointed Joseph Hooker as Interim Chief Executive Officer and President.
A sum of 6113874 shares traded at recent session while its average daily volume was at 3.93M shares. NeuroBo Pharmaceuticals Inc. shares reached a high of $0.8897 and dropped to a low of $0.76 until finishing in the latest session at $0.82.
The one-year NRBO stock forecast points to a potential upside of 86.33. The average equity rating for NRBO stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on NeuroBo Pharmaceuticals Inc. [NRBO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NRBO shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NRBO stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for NeuroBo Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 15, 2020.
The Average True Range (ATR) for NeuroBo Pharmaceuticals Inc. is set at 0.15 The Price to Book ratio for the last quarter was 0.12, with the Price to Cash per share for the same quarter was set at 0.39.
NRBO Stock Performance Analysis:
NeuroBo Pharmaceuticals Inc. [NRBO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.22. With this latest performance, NRBO shares dropped by -36.12% in over the last four-week period, additionally sinking by -93.97% over the last 6 months – not to mention a drop of -97.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NRBO stock in for the last two-week period is set at 38.81, with the RSI for the last a single of trading hit 48.92, and the three-weeks RSI is set at 36.69 for NeuroBo Pharmaceuticals Inc. [NRBO]. The present Moving Average for the last 50 days of trading for this stock 1.1541, while it was recorded at 0.7833 for the last single week of trading, and 10.9337 for the last 200 days.
Insight into NeuroBo Pharmaceuticals Inc. Fundamentals:
NeuroBo Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.70 and a Current Ratio set at 4.70.
NeuroBo Pharmaceuticals Inc. [NRBO] Insider Position Details
There are presently around $0 million, or 3.30% of NRBO stock, in the hands of institutional investors. The top three institutional holders of NRBO stocks are: VANGUARD GROUP INC with ownership of 11,393, which is approximately -30.805% of the company’s market cap and around 0.10% of the total institutional ownership; UBS GROUP AG, holding 3,765 shares of the stock with an approximate value of $3000.0 in NRBO stocks shares; and BLACKROCK INC., currently with $1000.0 in NRBO stock with ownership of nearly -0.141% of the company’s market capitalization.
2 institutional holders increased their position in NeuroBo Pharmaceuticals Inc. [NASDAQ:NRBO] by around 3,701 shares. Additionally, 19 investors decreased positions by around 28,431 shares, while 1 investors held positions by with 16,035 shares. The mentioned changes placed institutional holdings at 16,097 shares, according to the latest SEC report filing. NRBO stock had 1 new institutional investments in for a total of 38 shares, while 13 institutional investors sold positions of 23,023 shares during the same period.